Cd147 And Mmp-9 For The Diagnosis And Prognosis Evaluation Of Laryngeal Cancer

Objective: This study aimed to explore the value of extracellular matrix metalloproteinase inducer (EMMPRIN), also known as CD147, and matrix metalloproteinase 9 (MMP-9) in laryngeal cancer (LC). Methods: We measured the serum levels of CD147, MMP-9, C-reactive protein (CRP), and interleukin 6 (IL-6) in 51 LC patients (research group, RG) and 49 healthy participants (normal group, NG) using the enzyme-linked immunosorbent assay (ELISA) and detected the expression of CD147 and MMP-9 proteins in LC tissues to analyze their diagnostic and prognostic value in LC. Results: The serum levels of CD147, MMP-9, CRP, and IL-6 were markedly higher in RG than in NG. The positive expression rates of CD147, MMP-9, CRP, and IL-6 were markedly higher in LC tissues than those in adjacent tissues. The area under the curve (AUC) was 0.825 for CD147 and 0.886 for MMP-9 in diagnosing LC. The results of 3-year survival favored patients in the low expression groups over patients in the high expression groups and favored patients with negatively expressed CD147/MMP-9 over patients with positively expressed CD147/MMP-9. The receiver operating characteristic (ROC) curve suggested that CD147 and MMP-9 had a high predictive value for poor prognosis. Multivariate Cox regression analysis revealed that high CD147 and MMP-9 levels indicate a poor prognosis of LC. Conclusion: CD147 and MMP-9 levels were increased in the serum of patients with LC, so they can be used as potential serum biomarkers for the diagnosis and prognosis assessment in LC.